COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK (SESAME 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03511326
Recruitment Status : Completed
First Posted : April 27, 2018
Results First Posted : December 10, 2020
Last Update Posted : December 10, 2020
Information provided by (Responsible Party):

Brief Summary:
Interventional open label prospective and multicentre study conducted in Germany in subjects with thin or non-hyperkeratotic and non-pigmented multiple AKs in one anatomical area on the face (e.g., forehead or cheek or chin), excluding nose eyelids, lips and mucosa or balding scalp, using Luxerm® DL-PDT treatment.

Condition or disease Intervention/treatment Phase
Actinic Keratoses Drug: Methyl Aminolaevulinate 16% Cream Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp
Actual Study Start Date : June 7, 2017
Actual Primary Completion Date : November 28, 2017
Actual Study Completion Date : November 28, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Luxerm® Drug: Methyl Aminolaevulinate 16% Cream
Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy
Other Name: 160mg/g of methyl aminolevulinate

Primary Outcome Measures :
  1. Overall Subject Satisfaction the Day of Treatment After Daylight Session [ Time Frame: the day of treatment after daylight session ]
    Percentage of subjects satisfied and very satisfied globally with Luxerm Daylight procedure, the day of treatment after daylight session

  2. Overall Subject Satisfaction at Week 12 Post-treatment [ Time Frame: Week 12 ]
    Percentage of subjects satisfied or very satisfied (overall) with Luxerm DL procedure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female age > 18 years old.
  2. Subject with at least 5 clinically confirmed thin or non-hyperkeratotic and non-pigmented actinic keratoses in an anatomical area on the face (e.g., forehead or cheek or chin) excluding nose, eyelids, lips and mucosa, or balding scalp, at baseline visit.
  3. Subject or caregiver capable of performing the skin preparation and Luxerm® treatment application as per the investigator instructions.
  4. Female subject of childbearing potential must have a negative UPT at baseline (UPT should have a sensitivity of 25 IU/L or less) and agree to be strictly abstinent or use a highly effective method of birth control during the study (i.e. progestogen-only oral hormonal contraception; male or female condom; cap, diaphragm or sponge with spermicide; bilateral tubal ligation; combined (estrogen and progestogen-containing) oral hormonal contraception, or injectable or implants hormonal contraception (at a stable dose for at least 1 month prior to baseline); intra-uterine devices inserted at least 1 month prior to baseline; vasectomized partner for at least 3 months prior to baseline).
  5. Female subject of non-childbearing potential, e.g.: post-menopausal (absence of menstrual bleeding for 1 year without any other medical reason), hysterectomy or bilateral ovariectomy.
  6. Subject has read and signed the approved informed consent form (ICF) prior to any participation in the study.
  7. Subject has read and signed a Photograph Release Consent Form if he/she is willing to be photographed.
  8. Subject (or caregiver) willing and able to comply with all of the time commitments and procedural requirements of the clinical trial protocol.

Exclusion Criteria:

  1. Subject with a clinical diagnosis of a skin disease other than AK (including non-melanoma skin cancer) on the target anatomical area.
  2. Subject with severe AK (thick, hyperkeratotic AK) per anatomical area (face or scalp).
  3. Subject with clinical diagnosis of other skin disease on the target anatomical area.
  4. Subject with pigmented AK on the target anatomical area.
  5. Subject with melanoma at any location.
  6. Immunocompromised subject or requiring immunosuppressive therapies.
  7. Subject with porphyria; photosensitivity- related disorders, active infectious disease.
  8. Subject with known or suspected hypersensitivity to the active substance or to any excipients of Luxerm® (see Summary of Product Characteristics).
  9. Female subject who is pregnant, nursing or planning a pregnancy during the study.
  10. Subject who has used any of the following topical preparations on the area to be treated: keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g. glycolic acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%) within 2 days of initiation of treatment.
  11. Subject with a wash-out period from baseline for topical or systemic treatment or medical/surgical procedure in the anatomical area (for AKs) less than the following:

    • Retinoids, including tazarotene, adapalene, tretinoin, retinol ==> 4 weeks
    • Cryotherapy, diclofenac, corticosteroids or other treatments for AK==> 8 weeks
    • Microdermabrasion, laser ablative treatments or chemical peels ==>8 weeks
    • 5-FU, imiquimod ==>24 weeks
    • Surgical: excision and reconstructive surgery, chemosurgery, ==>12 weeks
    • Any Photodynamic Therapy, ingenol mebutate (Pep-005), Radiotherapy and UV radiation therapy==>12 weeks
    • Investigational therapies for Actinic Keratoses==>12 weeks
    • Immunosuppressive drugs (such as glucocorticoids, cytostatic, antibodies, drugs acting on interferon, opioids, TNF binding proteins, Mycophenolate, small biologics agents)==>12 weeks
  12. Subject who is currently participating to/ or who has participated in another investigational treatment or device research study within 4 weeks of baseline visit.
  13. Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits.
  14. Subject who is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
  15. Subject who is unwilling to refrain from use of prohibited medication during the clinical trial (see section 4.3.5).
  16. Subject who is vulnerable (such as deprived of freedom) as defined in Section 1.61 of the International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice (GCP).
  17. Subject with clinically significant abnormal laboratory finding (if any available report) at the baseline visit or medical/surgical condition (other than for actinic keratoses), which might, in the Investigator's opinion, interfere with study evaluations or pose a risk to subject safety during the study.
  18. The subject is a study site staff member (investigator, study nurse, etc.) or a relative of one.
  19. Subjects with any condition that may be associated with a risk of poor protocol compliance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03511326

Layout table for location information
University Hospital Regensburg
Regensburg, Germany
Sponsors and Collaborators
Layout table for investigator information
Study Director: Rajeev CHAVDA, MD Galderma
  Study Documents (Full-Text)

Documents provided by Galderma:
Layout table for additonal information
Responsible Party: Galderma Identifier: NCT03511326    
Other Study ID Numbers: RD.03.SPR.114384
First Posted: April 27, 2018    Key Record Dates
Results First Posted: December 10, 2020
Last Update Posted: December 10, 2020
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Galderma:
Additional relevant MeSH terms:
Layout table for MeSH terms
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Aminolevulinic Acid
Methyl 5-aminolevulinate
Photosensitizing Agents
Dermatologic Agents